MediciNova, Inc. (MNOV)
US — Healthcare Sector
Automate Your Wheel Strategy on MNOV
With Tiblio's Option Bot, you can configure your own wheel strategy including MNOV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MNOV
- Rev/Share 0.0
- Book/Share 1.018
- PB 1.2475
- Debt/Equity 0.0038
- CurrentRatio 17.6593
- ROIC -0.2525
- MktCap 62288674.0
- FreeCF/Share -0.2153
- PFCF -5.899
- PE -5.5819
- Debt/Assets 0.0036
- DivYield 0
- ROE -0.2077
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About MediciNova, Inc. (MNOV)
- IPO Date 2006-12-08
- Website https://www.medicinova.com
- Industry Biotechnology
- CEO Dr. Yuichi Iwaki M.D., Ph.D.
- Employees 13
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.